Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a daily pastille help fight recurrent brain tumors?

NCT ID NCT06011109

Recruiting now Disease control Sponsor: Aveta Biomics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study tests whether adding APG-157 (a pastille dissolved in the mouth) to standard bevacizumab can help people with recurrent high-grade glioma. About 30 participants will take APG-157 three times daily while continuing bevacizumab. The study tracks survival, tumor response on scans, and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
APG-157 (a pastille dissolved in the mouth) plus bevacizumab (standard of care)
What this could lead to
If it works, this combination could offer a new option to slow tumor growth and improve quality of life for patients with recurrent high-grade glioma.
What could go wrong
This is a small, early-phase pilot study with only 30 participants, so results may not apply broadly. The added benefit of APG-157 over bevacizumab alone is uncertain, and side effects are not yet well understood.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANAPLASTIC ASTROCYTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anaplastic astrocytoma anaplastic oligodendroglioma diffuse midline glioma, H3 K27M-mutant glioblastoma glioma glioma susceptibility 1 gliosarcoma malignant glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA MULTIFORME GLIOMA

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Mayo Clinic

    RECRUITING

    Rochester, Minnesota, 55905, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Nebraska Medical Center

    RECRUITING

    Omaha, Nebraska, 68198, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.